A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Synthesis of Site-Specific Antibody-[60]Fullerene-Oligonucleotide Conjugates for Cellular Targeting




TekijätÄärelä Antti, Räsänen Kati, Holm Patrik, Salo Harri, Virta Pasi

KustantajaAMER CHEMICAL SOC

Julkaisuvuosi2023

JournalACS Applied Bio Materials

Tietokannassa oleva lehden nimiACS APPLIED BIO MATERIALS

Lehden akronyymiACS APPL BIO MATER

Vuosikerta6

Numero8

Aloitussivu3189

Lopetussivu3198

Sivujen määrä10

ISSN2576-6422

eISSN2576-6422

DOIhttps://doi.org/10.1021/acsabm.3c00318

Verkko-osoitehttps://doi.org/10.1021/acsabm.3c00318

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/180411556


Tiivistelmä
An ideal therapeutic antibody-oligonucleotideconjugate(AOC) would be a uniform construct, contain a maximal oligonucleotide(ON) payload, and retain the antibody (Ab)-mediated binding properties,which leads to an efficient delivery of the ON cargo to the site oftherapeutic action. Herein, [60]fullerene-based molecular sphericalnucleic acids (MSNAs) have been site-specifically conjugated to antibodies(Abs), and the Ab-mediated cellular targeting of the MSNA-Abconjugates has been studied. A well-established glycan engineeringtechnology and robust orthogonal click chemistries yielded the desireduniform MSNA-Ab conjugates (MW & SIM; 270 kDa), with an oligonucleotide(ON):Ab ratio of 24:1, in 20-26% isolated yields. These AOCsretained the antigen binding properties (Trastuzumab's bindingto human epidermal growth factor receptor 2, HER2), studied by biolayerinterferometry. In addition, Ab-mediated endocytosis was demonstratedwith live-cell fluorescence and phase-contrast microscopy on BT-474breast carcinoma cells, overexpressing HER2. The effect on cell proliferationwas analyzed by label-free live-cell time-lapse imaging.

Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 10:33